A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2020; you can also visit the original URL.
The file type is
US Cardiology Review
Currently available antiarrhythmic drugs for the treatment of atrial fibrillation are limited in their efficacy and have potential for adverse effects, including torsade de pointes. With the aging of the population, the incidence of atrial fibrillation will double in frequency over the next 15 years.doi:10.15420/usc.2007.4.2.71 fatcat:xaxmv4lucjaw7ohxjywy4vwldu